http://www.xconomy.com Business + Technology in the Exponential Economy Fri, 10 Feb 2012 02:41:46 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/san-diego/comment-page-1/#comment-572467 San Diego and Entrepreneurial Communities | Hi, I'm David G. Cohen Fri, 27 Jan 2012 16:35:52 +0000 http://www.xconomy.com/san-diego/#comment-572467 [...] night, I was invited by Xconomy to come to San Diego and talk about entrepreneurial communities at a private dinner that had about [...] [...] night, I was invited by Xconomy to come to San Diego and talk about entrepreneurial communities at a private dinner that had about [...]

]]> http://www.xconomy.com/san-diego/comment-page-1/#comment-226982 Safeguard Scientifics Blog » Advanced BioHealing Profiled by Xconomy San Diego Thu, 30 Sep 2010 13:54:06 +0000 http://www.xconomy.com/san-diego/#comment-226982 [...] Bigelow of Xconomy San Diego highlights Advanced BioHealing’s (ABH) commercial success with Dermagraft in his article. [...] [...] Bigelow of Xconomy San Diego highlights Advanced BioHealing’s (ABH) commercial success with Dermagraft in his article. [...]

]]> http://www.xconomy.com/san-diego/comment-page-1/#comment-110478 Xconomy: San Diego’s Tioga Pharmaceuticals raises $18 million to develop IBS drug Fri, 19 Feb 2010 21:40:51 +0000 http://www.xconomy.com/san-diego/#comment-110478 [...] As I reported in last fall, Tioga acquired asimadoline from Germany-based Merck, which put the drug through early-stage trials before deciding it did not fit into Merck’s long-range plans. In return for equity in Tioga, Merck granted the startup rights to asimadoline and agreed to provide project management expertise. Taking Merck’s R&D costs into account, more than $100 million has been invested in the drug. [...] [...] As I reported in last fall, Tioga acquired asimadoline from Germany-based Merck, which put the drug through early-stage trials before deciding it did not fit into Merck’s long-range plans. In return for equity in Tioga, Merck granted the startup rights to asimadoline and agreed to provide project management expertise. Taking Merck’s R&D costs into account, more than $100 million has been invested in the drug. [...]

]]> http://www.xconomy.com/san-diego/comment-page-1/#comment-108501 Proposed ‘distributed partnering’ model addresses the innovation Valley of Death | Technology Transfer Tactics Wed, 27 Jan 2010 18:43:38 +0000 http://www.xconomy.com/san-diego/#comment-108501 [...] in Xconomy San Diego, CONNECT CEO Duane J. Roth describes a new funding model for innovation. The Distributed Partnering [...] [...] in Xconomy San Diego, CONNECT CEO Duane J. Roth describes a new funding model for innovation. The Distributed Partnering [...]

]]> http://www.xconomy.com/san-diego/comment-page-1/#comment-47453 Patent suit causes layoffs Wed, 25 Feb 2009 12:12:04 +0000 http://www.xconomy.com/san-diego/#comment-47453 [...] Xconomy is reporting that a suit filed by SkinMedica against Histogen caused Histogen to layoff all of its employees.  The suit was filed just prior to Histogen closing a round of financing with an investor group. [...] [...] Xconomy is reporting that a suit filed by SkinMedica against Histogen caused Histogen to layoff all of its employees.  The suit was filed just prior to Histogen closing a round of financing with an investor group. [...]

]]> http://www.xconomy.com/san-diego/comment-page-1/#comment-44391 Upcoming Studies and Speakers at Dr. Beyster’s Blog Tue, 13 Jan 2009 15:47:13 +0000 http://www.xconomy.com/san-diego/#comment-44391 [...] for Future Presidents. Former San Diego Union-Tribune reporter Bruce Bigelow is the Editor of Xconomy San Diego. The speaker — physicist Richard A. Muller — plans to “challenge conventional [...] [...] for Future Presidents. Former San Diego Union-Tribune reporter Bruce Bigelow is the Editor of Xconomy San Diego. The speaker — physicist Richard A. Muller — plans to “challenge conventional [...]

]]>